nodes	percent_of_prediction	percent_of_DWPC	metapath
Palonosetron—CYP2D6—Temsirolimus—kidney cancer	0.0899	0.136	CbGbCtD
Palonosetron—CYP3A4—Everolimus—kidney cancer	0.0846	0.128	CbGbCtD
Palonosetron—CYP1A2—Pazopanib—kidney cancer	0.0573	0.0865	CbGbCtD
Palonosetron—CYP3A4—Temsirolimus—kidney cancer	0.0572	0.0863	CbGbCtD
Palonosetron—CYP2D6—Pazopanib—kidney cancer	0.0472	0.0713	CbGbCtD
Palonosetron—CYP1A2—Erlotinib—kidney cancer	0.0409	0.0617	CbGbCtD
Palonosetron—CYP2D6—Erlotinib—kidney cancer	0.0337	0.0509	CbGbCtD
Palonosetron—CYP1A2—Sorafenib—kidney cancer	0.0333	0.0502	CbGbCtD
Palonosetron—CYP3A4—Pazopanib—kidney cancer	0.03	0.0453	CbGbCtD
Palonosetron—CYP2D6—Sorafenib—kidney cancer	0.0274	0.0414	CbGbCtD
Palonosetron—CYP2D6—Vinblastine—kidney cancer	0.0271	0.0408	CbGbCtD
Palonosetron—CYP3A4—Erlotinib—kidney cancer	0.0214	0.0323	CbGbCtD
Palonosetron—CYP3A4—Paclitaxel—kidney cancer	0.0196	0.0296	CbGbCtD
Palonosetron—CYP3A4—Sorafenib—kidney cancer	0.0174	0.0263	CbGbCtD
Palonosetron—CYP3A4—Vinblastine—kidney cancer	0.0172	0.026	CbGbCtD
Palonosetron—CYP3A4—Vincristine—kidney cancer	0.0169	0.0255	CbGbCtD
Palonosetron—CYP2D6—Doxorubicin—kidney cancer	0.0166	0.0251	CbGbCtD
Palonosetron—CYP3A4—Sunitinib—kidney cancer	0.0141	0.0213	CbGbCtD
Palonosetron—CYP3A4—Doxorubicin—kidney cancer	0.0106	0.016	CbGbCtD
Palonosetron—CYP1A2—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.000265	0.0451	CbGpPWpGaD
Palonosetron—HTR3A—Ion channel transport—RYR1—kidney cancer	0.000232	0.0394	CbGpPWpGaD
Palonosetron—Musculoskeletal discomfort—Vincristine—kidney cancer	0.00023	0.000694	CcSEcCtD
Palonosetron—Urinary tract disorder—Capecitabine—kidney cancer	0.000229	0.00069	CcSEcCtD
Palonosetron—Menopausal symptoms—Doxorubicin—kidney cancer	0.000229	0.00069	CcSEcCtD
Palonosetron—Hypersensitivity—Sorafenib—kidney cancer	0.000229	0.000689	CcSEcCtD
Palonosetron—Insomnia—Vincristine—kidney cancer	0.000228	0.000689	CcSEcCtD
Palonosetron—Anorexia—Gemcitabine—kidney cancer	0.000228	0.000688	CcSEcCtD
Palonosetron—Vomiting—Vinblastine—kidney cancer	0.000228	0.000688	CcSEcCtD
Palonosetron—Dizziness—Erlotinib—kidney cancer	0.000228	0.000688	CcSEcCtD
Palonosetron—Connective tissue disorder—Capecitabine—kidney cancer	0.000228	0.000686	CcSEcCtD
Palonosetron—Vomiting—Everolimus—kidney cancer	0.000227	0.000685	CcSEcCtD
Palonosetron—Anaemia—Paclitaxel—kidney cancer	0.000227	0.000685	CcSEcCtD
Palonosetron—Urethral disorder—Capecitabine—kidney cancer	0.000227	0.000685	CcSEcCtD
Palonosetron—Paraesthesia—Vincristine—kidney cancer	0.000227	0.000684	CcSEcCtD
Palonosetron—Rash—Everolimus—kidney cancer	0.000225	0.000679	CcSEcCtD
Palonosetron—Dermatitis—Everolimus—kidney cancer	0.000225	0.000679	CcSEcCtD
Palonosetron—Headache—Vinblastine—kidney cancer	0.000225	0.000678	CcSEcCtD
Palonosetron—Headache—Everolimus—kidney cancer	0.000224	0.000675	CcSEcCtD
Palonosetron—Hypotension—Gemcitabine—kidney cancer	0.000224	0.000675	CcSEcCtD
Palonosetron—Abdominal pain—Dactinomycin—kidney cancer	0.000223	0.000674	CcSEcCtD
Palonosetron—Body temperature increased—Dactinomycin—kidney cancer	0.000223	0.000674	CcSEcCtD
Palonosetron—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.000223	0.000672	CcSEcCtD
Palonosetron—Asthenia—Sorafenib—kidney cancer	0.000223	0.000671	CcSEcCtD
Palonosetron—Hypersensitivity—Sunitinib—kidney cancer	0.00022	0.000663	CcSEcCtD
Palonosetron—Decreased appetite—Vincristine—kidney cancer	0.000219	0.000662	CcSEcCtD
Palonosetron—Pruritus—Sorafenib—kidney cancer	0.000219	0.000662	CcSEcCtD
Palonosetron—Vomiting—Erlotinib—kidney cancer	0.000219	0.000661	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000218	0.000658	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Vincristine—kidney cancer	0.000218	0.000657	CcSEcCtD
Palonosetron—Fatigue—Vincristine—kidney cancer	0.000218	0.000656	CcSEcCtD
Palonosetron—Rash—Erlotinib—kidney cancer	0.000217	0.000656	CcSEcCtD
Palonosetron—Dermatitis—Erlotinib—kidney cancer	0.000217	0.000655	CcSEcCtD
Palonosetron—Insomnia—Gemcitabine—kidney cancer	0.000217	0.000653	CcSEcCtD
Palonosetron—Eye disorder—Capecitabine—kidney cancer	0.000216	0.000653	CcSEcCtD
Palonosetron—Headache—Erlotinib—kidney cancer	0.000216	0.000651	CcSEcCtD
Palonosetron—Tinnitus—Capecitabine—kidney cancer	0.000216	0.000651	CcSEcCtD
Palonosetron—Pain—Vincristine—kidney cancer	0.000216	0.000651	CcSEcCtD
Palonosetron—Constipation—Vincristine—kidney cancer	0.000216	0.000651	CcSEcCtD
Palonosetron—Pain in extremity—Doxorubicin—kidney cancer	0.000216	0.000651	CcSEcCtD
Palonosetron—Paraesthesia—Gemcitabine—kidney cancer	0.000215	0.000648	CcSEcCtD
Palonosetron—Cardiac disorder—Capecitabine—kidney cancer	0.000215	0.000648	CcSEcCtD
Palonosetron—Asthenia—Sunitinib—kidney cancer	0.000214	0.000646	CcSEcCtD
Palonosetron—Dyspnoea—Gemcitabine—kidney cancer	0.000214	0.000644	CcSEcCtD
Palonosetron—Nausea—Vinblastine—kidney cancer	0.000213	0.000643	CcSEcCtD
Palonosetron—Somnolence—Gemcitabine—kidney cancer	0.000213	0.000642	CcSEcCtD
Palonosetron—Convulsion—Paclitaxel—kidney cancer	0.000213	0.000642	CcSEcCtD
Palonosetron—Nausea—Everolimus—kidney cancer	0.000212	0.00064	CcSEcCtD
Palonosetron—Diarrhoea—Sorafenib—kidney cancer	0.000212	0.00064	CcSEcCtD
Palonosetron—Hypertension—Paclitaxel—kidney cancer	0.000212	0.00064	CcSEcCtD
Palonosetron—Pruritus—Sunitinib—kidney cancer	0.000211	0.000637	CcSEcCtD
Palonosetron—Angiopathy—Capecitabine—kidney cancer	0.00021	0.000634	CcSEcCtD
Palonosetron—Immune system disorder—Capecitabine—kidney cancer	0.000209	0.000631	CcSEcCtD
Palonosetron—Myalgia—Paclitaxel—kidney cancer	0.000209	0.000631	CcSEcCtD
Palonosetron—Arthralgia—Paclitaxel—kidney cancer	0.000209	0.000631	CcSEcCtD
Palonosetron—Mediastinal disorder—Capecitabine—kidney cancer	0.000209	0.000629	CcSEcCtD
Palonosetron—Anxiety—Paclitaxel—kidney cancer	0.000208	0.000629	CcSEcCtD
Palonosetron—Decreased appetite—Gemcitabine—kidney cancer	0.000208	0.000628	CcSEcCtD
Palonosetron—Hypersensitivity—Dactinomycin—kidney cancer	0.000208	0.000628	CcSEcCtD
Palonosetron—Chills—Capecitabine—kidney cancer	0.000208	0.000627	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000208	0.000626	CcSEcCtD
Palonosetron—Arrhythmia—Capecitabine—kidney cancer	0.000207	0.000624	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000207	0.000623	CcSEcCtD
Palonosetron—Discomfort—Paclitaxel—kidney cancer	0.000207	0.000623	CcSEcCtD
Palonosetron—Fatigue—Gemcitabine—kidney cancer	0.000206	0.000623	CcSEcCtD
Palonosetron—Gastrointestinal pain—Vincristine—kidney cancer	0.000206	0.000623	CcSEcCtD
Palonosetron—Dizziness—Sorafenib—kidney cancer	0.000205	0.000619	CcSEcCtD
Palonosetron—Constipation—Gemcitabine—kidney cancer	0.000205	0.000618	CcSEcCtD
Palonosetron—Pain—Gemcitabine—kidney cancer	0.000205	0.000618	CcSEcCtD
Palonosetron—CYP3A4—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.000205	0.0348	CbGpPWpGaD
Palonosetron—Nausea—Erlotinib—kidney cancer	0.000205	0.000618	CcSEcCtD
Palonosetron—Alopecia—Capecitabine—kidney cancer	0.000205	0.000617	CcSEcCtD
Palonosetron—Dry mouth—Paclitaxel—kidney cancer	0.000205	0.000617	CcSEcCtD
Palonosetron—Diarrhoea—Sunitinib—kidney cancer	0.000204	0.000616	CcSEcCtD
Palonosetron—Mental disorder—Capecitabine—kidney cancer	0.000203	0.000612	CcSEcCtD
Palonosetron—Asthenia—Dactinomycin—kidney cancer	0.000203	0.000611	CcSEcCtD
Palonosetron—Erythema—Capecitabine—kidney cancer	0.000202	0.000608	CcSEcCtD
Palonosetron—Malnutrition—Capecitabine—kidney cancer	0.000202	0.000608	CcSEcCtD
Palonosetron—Anaphylactic shock—Paclitaxel—kidney cancer	0.000201	0.000605	CcSEcCtD
Palonosetron—Abdominal pain—Vincristine—kidney cancer	0.0002	0.000602	CcSEcCtD
Palonosetron—Body temperature increased—Vincristine—kidney cancer	0.0002	0.000602	CcSEcCtD
Palonosetron—Infection—Paclitaxel—kidney cancer	0.000199	0.000601	CcSEcCtD
Palonosetron—Flatulence—Capecitabine—kidney cancer	0.000199	0.000599	CcSEcCtD
Palonosetron—Dysgeusia—Capecitabine—kidney cancer	0.000197	0.000595	CcSEcCtD
Palonosetron—Dizziness—Sunitinib—kidney cancer	0.000197	0.000595	CcSEcCtD
Palonosetron—Shock—Paclitaxel—kidney cancer	0.000197	0.000595	CcSEcCtD
Palonosetron—Vomiting—Sorafenib—kidney cancer	0.000197	0.000595	CcSEcCtD
Palonosetron—Abdominal pain upper—Doxorubicin—kidney cancer	0.000197	0.000594	CcSEcCtD
Palonosetron—CYP2D6—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.000197	0.0335	CbGpPWpGaD
Palonosetron—Nervous system disorder—Paclitaxel—kidney cancer	0.000197	0.000593	CcSEcCtD
Palonosetron—Hypokalaemia—Doxorubicin—kidney cancer	0.000196	0.000592	CcSEcCtD
Palonosetron—Tachycardia—Paclitaxel—kidney cancer	0.000196	0.00059	CcSEcCtD
Palonosetron—Rash—Sorafenib—kidney cancer	0.000196	0.00059	CcSEcCtD
Palonosetron—Dermatitis—Sorafenib—kidney cancer	0.000195	0.000589	CcSEcCtD
Palonosetron—Skin disorder—Paclitaxel—kidney cancer	0.000195	0.000587	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000194	0.000586	CcSEcCtD
Palonosetron—Headache—Sorafenib—kidney cancer	0.000194	0.000586	CcSEcCtD
Palonosetron—Diarrhoea—Dactinomycin—kidney cancer	0.000193	0.000583	CcSEcCtD
Palonosetron—Anorexia—Paclitaxel—kidney cancer	0.000191	0.000576	CcSEcCtD
Palonosetron—Gastritis—Doxorubicin—kidney cancer	0.000191	0.000576	CcSEcCtD
Palonosetron—Vomiting—Sunitinib—kidney cancer	0.00019	0.000572	CcSEcCtD
Palonosetron—Body temperature increased—Gemcitabine—kidney cancer	0.000189	0.000571	CcSEcCtD
Palonosetron—Rash—Sunitinib—kidney cancer	0.000188	0.000567	CcSEcCtD
Palonosetron—Dermatitis—Sunitinib—kidney cancer	0.000188	0.000567	CcSEcCtD
Palonosetron—Abdominal distension—Doxorubicin—kidney cancer	0.000188	0.000566	CcSEcCtD
Palonosetron—Hypotension—Paclitaxel—kidney cancer	0.000187	0.000565	CcSEcCtD
Palonosetron—Headache—Sunitinib—kidney cancer	0.000187	0.000564	CcSEcCtD
Palonosetron—Anaemia—Capecitabine—kidney cancer	0.000186	0.000562	CcSEcCtD
Palonosetron—Hypersensitivity—Vincristine—kidney cancer	0.000186	0.000561	CcSEcCtD
Palonosetron—Nausea—Sorafenib—kidney cancer	0.000184	0.000556	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000183	0.000551	CcSEcCtD
Palonosetron—Insomnia—Paclitaxel—kidney cancer	0.000181	0.000547	CcSEcCtD
Palonosetron—Asthenia—Vincristine—kidney cancer	0.000181	0.000546	CcSEcCtD
Palonosetron—Paraesthesia—Paclitaxel—kidney cancer	0.00018	0.000543	CcSEcCtD
Palonosetron—Vomiting—Dactinomycin—kidney cancer	0.00018	0.000542	CcSEcCtD
Palonosetron—Dyspnoea—Paclitaxel—kidney cancer	0.000179	0.000539	CcSEcCtD
Palonosetron—Somnolence—Paclitaxel—kidney cancer	0.000178	0.000538	CcSEcCtD
Palonosetron—Rash—Dactinomycin—kidney cancer	0.000178	0.000537	CcSEcCtD
Palonosetron—Nausea—Sunitinib—kidney cancer	0.000177	0.000535	CcSEcCtD
Palonosetron—Dyspepsia—Paclitaxel—kidney cancer	0.000176	0.000532	CcSEcCtD
Palonosetron—Decreased appetite—Paclitaxel—kidney cancer	0.000174	0.000526	CcSEcCtD
Palonosetron—Hypertension—Capecitabine—kidney cancer	0.000174	0.000525	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000173	0.000522	CcSEcCtD
Palonosetron—Fatigue—Paclitaxel—kidney cancer	0.000173	0.000521	CcSEcCtD
Palonosetron—Diarrhoea—Vincristine—kidney cancer	0.000173	0.000521	CcSEcCtD
Palonosetron—Asthenia—Gemcitabine—kidney cancer	0.000172	0.000518	CcSEcCtD
Palonosetron—Arthralgia—Capecitabine—kidney cancer	0.000172	0.000518	CcSEcCtD
Palonosetron—Myalgia—Capecitabine—kidney cancer	0.000172	0.000518	CcSEcCtD
Palonosetron—Constipation—Paclitaxel—kidney cancer	0.000171	0.000517	CcSEcCtD
Palonosetron—Pain—Paclitaxel—kidney cancer	0.000171	0.000517	CcSEcCtD
Palonosetron—Anxiety—Capecitabine—kidney cancer	0.000171	0.000516	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.00017	0.000514	CcSEcCtD
Palonosetron—Discomfort—Capecitabine—kidney cancer	0.00017	0.000511	CcSEcCtD
Palonosetron—Pruritus—Gemcitabine—kidney cancer	0.000169	0.000511	CcSEcCtD
Palonosetron—Hyperglycaemia—Doxorubicin—kidney cancer	0.000168	0.000507	CcSEcCtD
Palonosetron—Dry mouth—Capecitabine—kidney cancer	0.000168	0.000506	CcSEcCtD
Palonosetron—Nausea—Dactinomycin—kidney cancer	0.000168	0.000506	CcSEcCtD
Palonosetron—Dizziness—Vincristine—kidney cancer	0.000167	0.000503	CcSEcCtD
Palonosetron—CYP1A2—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.000167	0.0284	CbGpPWpGaD
Palonosetron—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000164	0.000494	CcSEcCtD
Palonosetron—Diarrhoea—Gemcitabine—kidney cancer	0.000164	0.000494	CcSEcCtD
Palonosetron—Infection—Capecitabine—kidney cancer	0.000163	0.000493	CcSEcCtD
Palonosetron—Shock—Capecitabine—kidney cancer	0.000162	0.000488	CcSEcCtD
Palonosetron—Nervous system disorder—Capecitabine—kidney cancer	0.000161	0.000487	CcSEcCtD
Palonosetron—Tachycardia—Capecitabine—kidney cancer	0.000161	0.000484	CcSEcCtD
Palonosetron—Vomiting—Vincristine—kidney cancer	0.000161	0.000484	CcSEcCtD
Palonosetron—Skin disorder—Capecitabine—kidney cancer	0.00016	0.000482	CcSEcCtD
Palonosetron—Rash—Vincristine—kidney cancer	0.000159	0.00048	CcSEcCtD
Palonosetron—Dermatitis—Vincristine—kidney cancer	0.000159	0.00048	CcSEcCtD
Palonosetron—Body temperature increased—Paclitaxel—kidney cancer	0.000159	0.000478	CcSEcCtD
Palonosetron—Abdominal pain—Paclitaxel—kidney cancer	0.000159	0.000478	CcSEcCtD
Palonosetron—Headache—Vincristine—kidney cancer	0.000158	0.000477	CcSEcCtD
Palonosetron—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000157	0.000474	CcSEcCtD
Palonosetron—Epistaxis—Doxorubicin—kidney cancer	0.000157	0.000473	CcSEcCtD
Palonosetron—Anorexia—Capecitabine—kidney cancer	0.000157	0.000473	CcSEcCtD
Palonosetron—Sinusitis—Doxorubicin—kidney cancer	0.000156	0.000471	CcSEcCtD
Palonosetron—Hypotension—Capecitabine—kidney cancer	0.000154	0.000464	CcSEcCtD
Palonosetron—Vomiting—Gemcitabine—kidney cancer	0.000152	0.000459	CcSEcCtD
Palonosetron—Bradycardia—Doxorubicin—kidney cancer	0.000152	0.000458	CcSEcCtD
Palonosetron—Rash—Gemcitabine—kidney cancer	0.000151	0.000455	CcSEcCtD
Palonosetron—Dermatitis—Gemcitabine—kidney cancer	0.000151	0.000455	CcSEcCtD
Palonosetron—Headache—Gemcitabine—kidney cancer	0.00015	0.000452	CcSEcCtD
Palonosetron—Nausea—Vincristine—kidney cancer	0.00015	0.000452	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.00015	0.000452	CcSEcCtD
Palonosetron—Insomnia—Capecitabine—kidney cancer	0.000149	0.000449	CcSEcCtD
Palonosetron—Paraesthesia—Capecitabine—kidney cancer	0.000148	0.000446	CcSEcCtD
Palonosetron—Hypersensitivity—Paclitaxel—kidney cancer	0.000148	0.000445	CcSEcCtD
Palonosetron—Urinary tract disorder—Doxorubicin—kidney cancer	0.000147	0.000445	CcSEcCtD
Palonosetron—Connective tissue disorder—Doxorubicin—kidney cancer	0.000147	0.000442	CcSEcCtD
Palonosetron—Dyspnoea—Capecitabine—kidney cancer	0.000147	0.000442	CcSEcCtD
Palonosetron—Urethral disorder—Doxorubicin—kidney cancer	0.000146	0.000441	CcSEcCtD
Palonosetron—Dyspepsia—Capecitabine—kidney cancer	0.000145	0.000437	CcSEcCtD
Palonosetron—Asthenia—Paclitaxel—kidney cancer	0.000144	0.000434	CcSEcCtD
Palonosetron—Decreased appetite—Capecitabine—kidney cancer	0.000143	0.000431	CcSEcCtD
Palonosetron—Nausea—Gemcitabine—kidney cancer	0.000142	0.000429	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000142	0.000428	CcSEcCtD
Palonosetron—Fatigue—Capecitabine—kidney cancer	0.000142	0.000428	CcSEcCtD
Palonosetron—Pruritus—Paclitaxel—kidney cancer	0.000142	0.000428	CcSEcCtD
Palonosetron—Pain—Capecitabine—kidney cancer	0.000141	0.000424	CcSEcCtD
Palonosetron—Constipation—Capecitabine—kidney cancer	0.000141	0.000424	CcSEcCtD
Palonosetron—Eye disorder—Doxorubicin—kidney cancer	0.00014	0.000421	CcSEcCtD
Palonosetron—Tinnitus—Doxorubicin—kidney cancer	0.000139	0.00042	CcSEcCtD
Palonosetron—Cardiac disorder—Doxorubicin—kidney cancer	0.000139	0.000418	CcSEcCtD
Palonosetron—Diarrhoea—Paclitaxel—kidney cancer	0.000137	0.000414	CcSEcCtD
Palonosetron—Angiopathy—Doxorubicin—kidney cancer	0.000135	0.000408	CcSEcCtD
Palonosetron—Immune system disorder—Doxorubicin—kidney cancer	0.000135	0.000407	CcSEcCtD
Palonosetron—Gastrointestinal pain—Capecitabine—kidney cancer	0.000135	0.000406	CcSEcCtD
Palonosetron—Mediastinal disorder—Doxorubicin—kidney cancer	0.000135	0.000406	CcSEcCtD
Palonosetron—Chills—Doxorubicin—kidney cancer	0.000134	0.000404	CcSEcCtD
Palonosetron—Arrhythmia—Doxorubicin—kidney cancer	0.000133	0.000402	CcSEcCtD
Palonosetron—HTR3A—Ion channel transport—ATP7B—kidney cancer	0.000133	0.0226	CbGpPWpGaD
Palonosetron—Dizziness—Paclitaxel—kidney cancer	0.000133	0.0004	CcSEcCtD
Palonosetron—CYP2D6—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.000132	0.0225	CbGpPWpGaD
Palonosetron—Alopecia—Doxorubicin—kidney cancer	0.000132	0.000398	CcSEcCtD
Palonosetron—Mental disorder—Doxorubicin—kidney cancer	0.000131	0.000394	CcSEcCtD
Palonosetron—Abdominal pain—Capecitabine—kidney cancer	0.00013	0.000392	CcSEcCtD
Palonosetron—Body temperature increased—Capecitabine—kidney cancer	0.00013	0.000392	CcSEcCtD
Palonosetron—Malnutrition—Doxorubicin—kidney cancer	0.00013	0.000392	CcSEcCtD
Palonosetron—Erythema—Doxorubicin—kidney cancer	0.00013	0.000392	CcSEcCtD
Palonosetron—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.000129	0.0219	CbGpPWpGaD
Palonosetron—Flatulence—Doxorubicin—kidney cancer	0.000128	0.000386	CcSEcCtD
Palonosetron—Vomiting—Paclitaxel—kidney cancer	0.000127	0.000384	CcSEcCtD
Palonosetron—Dysgeusia—Doxorubicin—kidney cancer	0.000127	0.000384	CcSEcCtD
Palonosetron—Rash—Paclitaxel—kidney cancer	0.000126	0.000381	CcSEcCtD
Palonosetron—Dermatitis—Paclitaxel—kidney cancer	0.000126	0.000381	CcSEcCtD
Palonosetron—Headache—Paclitaxel—kidney cancer	0.000126	0.000379	CcSEcCtD
Palonosetron—Hypersensitivity—Capecitabine—kidney cancer	0.000121	0.000366	CcSEcCtD
Palonosetron—CYP1A2—Aflatoxin B1 metabolism—GSTM1—kidney cancer	0.000121	0.0206	CbGpPWpGaD
Palonosetron—Anaemia—Doxorubicin—kidney cancer	0.00012	0.000362	CcSEcCtD
Palonosetron—Nausea—Paclitaxel—kidney cancer	0.000119	0.000359	CcSEcCtD
Palonosetron—Asthenia—Capecitabine—kidney cancer	0.000118	0.000356	CcSEcCtD
Palonosetron—Pruritus—Capecitabine—kidney cancer	0.000116	0.000351	CcSEcCtD
Palonosetron—Convulsion—Doxorubicin—kidney cancer	0.000113	0.00034	CcSEcCtD
Palonosetron—Diarrhoea—Capecitabine—kidney cancer	0.000113	0.00034	CcSEcCtD
Palonosetron—Hypertension—Doxorubicin—kidney cancer	0.000112	0.000338	CcSEcCtD
Palonosetron—Myalgia—Doxorubicin—kidney cancer	0.000111	0.000334	CcSEcCtD
Palonosetron—Arthralgia—Doxorubicin—kidney cancer	0.000111	0.000334	CcSEcCtD
Palonosetron—Anxiety—Doxorubicin—kidney cancer	0.00011	0.000333	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.00011	0.000331	CcSEcCtD
Palonosetron—Discomfort—Doxorubicin—kidney cancer	0.000109	0.00033	CcSEcCtD
Palonosetron—Dizziness—Capecitabine—kidney cancer	0.000109	0.000328	CcSEcCtD
Palonosetron—Dry mouth—Doxorubicin—kidney cancer	0.000108	0.000326	CcSEcCtD
Palonosetron—Anaphylactic shock—Doxorubicin—kidney cancer	0.000106	0.00032	CcSEcCtD
Palonosetron—Infection—Doxorubicin—kidney cancer	0.000105	0.000318	CcSEcCtD
Palonosetron—Vomiting—Capecitabine—kidney cancer	0.000105	0.000315	CcSEcCtD
Palonosetron—Shock—Doxorubicin—kidney cancer	0.000104	0.000315	CcSEcCtD
Palonosetron—Nervous system disorder—Doxorubicin—kidney cancer	0.000104	0.000314	CcSEcCtD
Palonosetron—Rash—Capecitabine—kidney cancer	0.000104	0.000313	CcSEcCtD
Palonosetron—Dermatitis—Capecitabine—kidney cancer	0.000104	0.000313	CcSEcCtD
Palonosetron—Tachycardia—Doxorubicin—kidney cancer	0.000104	0.000312	CcSEcCtD
Palonosetron—Headache—Capecitabine—kidney cancer	0.000103	0.000311	CcSEcCtD
Palonosetron—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—kidney cancer	0.000103	0.0175	CbGpPWpGaD
Palonosetron—Skin disorder—Doxorubicin—kidney cancer	0.000103	0.000311	CcSEcCtD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—HSPD1—kidney cancer	0.000102	0.0173	CbGpPWpGaD
Palonosetron—Anorexia—Doxorubicin—kidney cancer	0.000101	0.000305	CcSEcCtD
Palonosetron—Hypotension—Doxorubicin—kidney cancer	9.91e-05	0.000299	CcSEcCtD
Palonosetron—Nausea—Capecitabine—kidney cancer	9.77e-05	0.000295	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Doxorubicin—kidney cancer	9.66e-05	0.000291	CcSEcCtD
Palonosetron—Insomnia—Doxorubicin—kidney cancer	9.59e-05	0.000289	CcSEcCtD
Palonosetron—Paraesthesia—Doxorubicin—kidney cancer	9.52e-05	0.000287	CcSEcCtD
Palonosetron—Dyspnoea—Doxorubicin—kidney cancer	9.46e-05	0.000285	CcSEcCtD
Palonosetron—Somnolence—Doxorubicin—kidney cancer	9.43e-05	0.000284	CcSEcCtD
Palonosetron—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—kidney cancer	9.38e-05	0.016	CbGpPWpGaD
Palonosetron—Dyspepsia—Doxorubicin—kidney cancer	9.34e-05	0.000282	CcSEcCtD
Palonosetron—CYP3A4—Aflatoxin B1 metabolism—GSTM1—kidney cancer	9.34e-05	0.0159	CbGpPWpGaD
Palonosetron—Decreased appetite—Doxorubicin—kidney cancer	9.22e-05	0.000278	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Doxorubicin—kidney cancer	9.16e-05	0.000276	CcSEcCtD
Palonosetron—Fatigue—Doxorubicin—kidney cancer	9.14e-05	0.000276	CcSEcCtD
Palonosetron—Pain—Doxorubicin—kidney cancer	9.07e-05	0.000274	CcSEcCtD
Palonosetron—Constipation—Doxorubicin—kidney cancer	9.07e-05	0.000274	CcSEcCtD
Palonosetron—Gastrointestinal pain—Doxorubicin—kidney cancer	8.67e-05	0.000262	CcSEcCtD
Palonosetron—CYP3A4—Codeine and Morphine Metabolism—ABCB1—kidney cancer	8.64e-05	0.0147	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—IL13—kidney cancer	8.56e-05	0.0146	CbGpPWpGaD
Palonosetron—Body temperature increased—Doxorubicin—kidney cancer	8.38e-05	0.000253	CcSEcCtD
Palonosetron—Abdominal pain—Doxorubicin—kidney cancer	8.38e-05	0.000253	CcSEcCtD
Palonosetron—HTR3A—Transmembrane transport of small molecules—RYR1—kidney cancer	8.06e-05	0.0137	CbGpPWpGaD
Palonosetron—Hypersensitivity—Doxorubicin—kidney cancer	7.81e-05	0.000236	CcSEcCtD
Palonosetron—Asthenia—Doxorubicin—kidney cancer	7.61e-05	0.000229	CcSEcCtD
Palonosetron—Pruritus—Doxorubicin—kidney cancer	7.5e-05	0.000226	CcSEcCtD
Palonosetron—CYP3A4—Irinotecan Pathway—BCHE—kidney cancer	7.33e-05	0.0125	CbGpPWpGaD
Palonosetron—Diarrhoea—Doxorubicin—kidney cancer	7.26e-05	0.000219	CcSEcCtD
Palonosetron—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—kidney cancer	7.24e-05	0.0123	CbGpPWpGaD
Palonosetron—CYP2D6—Melatonin metabolism and effects—ACHE—kidney cancer	7.19e-05	0.0122	CbGpPWpGaD
Palonosetron—CYP1A2—Tryptophan metabolism—ALDH1A1—kidney cancer	7.17e-05	0.0122	CbGpPWpGaD
Palonosetron—Dizziness—Doxorubicin—kidney cancer	7.01e-05	0.000212	CcSEcCtD
Palonosetron—CYP1A2—Estrogen Receptor Pathway—CYP1A1—kidney cancer	6.99e-05	0.0119	CbGpPWpGaD
Palonosetron—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	6.99e-05	0.0119	CbGpPWpGaD
Palonosetron—Vomiting—Doxorubicin—kidney cancer	6.74e-05	0.000203	CcSEcCtD
Palonosetron—Rash—Doxorubicin—kidney cancer	6.69e-05	0.000202	CcSEcCtD
Palonosetron—Dermatitis—Doxorubicin—kidney cancer	6.68e-05	0.000201	CcSEcCtD
Palonosetron—Headache—Doxorubicin—kidney cancer	6.64e-05	0.0002	CcSEcCtD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—EGR1—kidney cancer	6.48e-05	0.011	CbGpPWpGaD
Palonosetron—Nausea—Doxorubicin—kidney cancer	6.3e-05	0.00019	CcSEcCtD
Palonosetron—CYP1A2—Melatonin metabolism and effects—ACHE—kidney cancer	6.09e-05	0.0104	CbGpPWpGaD
Palonosetron—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	5.92e-05	0.0101	CbGpPWpGaD
Palonosetron—CYP2D6—Xenobiotics—CYP1A1—kidney cancer	5.84e-05	0.00994	CbGpPWpGaD
Palonosetron—CYP1A2—Estrogen metabolism—GSTM1—kidney cancer	5.68e-05	0.00966	CbGpPWpGaD
Palonosetron—CYP2D6—Tamoxifen metabolism—CYP1A1—kidney cancer	5.62e-05	0.00956	CbGpPWpGaD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	5.55e-05	0.00943	CbGpPWpGaD
Palonosetron—CYP3A4—Tryptophan metabolism—ALDH1A1—kidney cancer	5.53e-05	0.00941	CbGpPWpGaD
Palonosetron—CYP1A2—Estrogen metabolism—CYP1A1—kidney cancer	5.39e-05	0.00916	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—ACY1—kidney cancer	5.38e-05	0.00914	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUND—kidney cancer	5.11e-05	0.00868	CbGpPWpGaD
Palonosetron—CYP1A2—Xenobiotics—CYP1A1—kidney cancer	4.95e-05	0.00842	CbGpPWpGaD
Palonosetron—CYP1A2—Tamoxifen metabolism—CYP1A1—kidney cancer	4.76e-05	0.0081	CbGpPWpGaD
Palonosetron—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	4.73e-05	0.00804	CbGpPWpGaD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	4.7e-05	0.00799	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—ANXA2—kidney cancer	4.63e-05	0.00787	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—SLC5A3—kidney cancer	4.63e-05	0.00787	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—ATP7B—kidney cancer	4.63e-05	0.00787	CbGpPWpGaD
Palonosetron—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	4.57e-05	0.00777	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—ACY1—kidney cancer	4.55e-05	0.00774	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—HIF1A—kidney cancer	4.51e-05	0.00767	CbGpPWpGaD
Palonosetron—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	4.39e-05	0.00746	CbGpPWpGaD
Palonosetron—CYP2D6—Melatonin metabolism and effects—CYP1A1—kidney cancer	4.34e-05	0.00738	CbGpPWpGaD
Palonosetron—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	4.16e-05	0.00707	CbGpPWpGaD
Palonosetron—CYP3A4—Irinotecan Pathway—APC—kidney cancer	3.98e-05	0.00677	CbGpPWpGaD
Palonosetron—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	3.82e-05	0.0065	CbGpPWpGaD
Palonosetron—CYP1A2—Estrogen Receptor Pathway—JUN—kidney cancer	3.75e-05	0.00637	CbGpPWpGaD
Palonosetron—CYP1A2—Arachidonic acid metabolism—PTGS1—kidney cancer	3.69e-05	0.00628	CbGpPWpGaD
Palonosetron—CYP1A2—Melatonin metabolism and effects—CYP1A1—kidney cancer	3.68e-05	0.00626	CbGpPWpGaD
Palonosetron—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	3.68e-05	0.00625	CbGpPWpGaD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	3.63e-05	0.00617	CbGpPWpGaD
Palonosetron—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	3.52e-05	0.00598	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—ACY1—kidney cancer	3.51e-05	0.00598	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUNB—kidney cancer	3.47e-05	0.00591	CbGpPWpGaD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	3.05e-05	0.00519	CbGpPWpGaD
Palonosetron—HTR3A—Ion channel transport—RAF1—kidney cancer	3.03e-05	0.00515	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—ALDH1A1—kidney cancer	2.95e-05	0.00501	CbGpPWpGaD
Palonosetron—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	2.85e-05	0.00485	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—JUN—kidney cancer	2.72e-05	0.00463	CbGpPWpGaD
Palonosetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	2.72e-05	0.00462	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—CTNNB1—kidney cancer	2.7e-05	0.00459	CbGpPWpGaD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	2.59e-05	0.0044	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—kidney cancer	2.54e-05	0.00432	CbGpPWpGaD
Palonosetron—CYP1A2—Tryptophan metabolism—CYP1A1—kidney cancer	2.54e-05	0.00432	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—kidney cancer	2.54e-05	0.00432	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—GSTT1—kidney cancer	2.51e-05	0.00426	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—ALDH1A1—kidney cancer	2.5e-05	0.00424	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—SLC5A5—kidney cancer	2.44e-05	0.00415	CbGpPWpGaD
Palonosetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	2.43e-05	0.00413	CbGpPWpGaD
Palonosetron—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	2.4e-05	0.00407	CbGpPWpGaD
Palonosetron—CYP1A2—Arachidonic acid metabolism—CYP1A1—kidney cancer	2.38e-05	0.00405	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—VEGFA—kidney cancer	2.38e-05	0.00404	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—SLC2A1—kidney cancer	2.36e-05	0.00401	CbGpPWpGaD
Palonosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	2.06e-05	0.0035	CbGpPWpGaD
Palonosetron—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	2.03e-05	0.00345	CbGpPWpGaD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	2e-05	0.00339	CbGpPWpGaD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	1.97e-05	0.00335	CbGpPWpGaD
Palonosetron—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	1.96e-05	0.00334	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	1.93e-05	0.00327	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.86e-05	0.00317	CbGpPWpGaD
Palonosetron—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	1.81e-05	0.00308	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—GSTP1—kidney cancer	1.74e-05	0.00295	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GSTT1—kidney cancer	1.73e-05	0.00294	CbGpPWpGaD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	1.67e-05	0.00283	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—PTGS1—kidney cancer	1.62e-05	0.00276	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—GSTM1—kidney cancer	1.6e-05	0.00271	CbGpPWpGaD
Palonosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	1.59e-05	0.0027	CbGpPWpGaD
Palonosetron—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	1.57e-05	0.00266	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—kidney cancer	1.56e-05	0.00266	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—RELA—kidney cancer	1.56e-05	0.00265	CbGpPWpGaD
Palonosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	1.53e-05	0.00261	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—kidney cancer	1.51e-05	0.00257	CbGpPWpGaD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—POMC—kidney cancer	1.47e-05	0.00249	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GSTT1—kidney cancer	1.47e-05	0.00249	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	1.43e-05	0.00244	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	1.43e-05	0.00244	CbGpPWpGaD
Palonosetron—CYP1A2—Arachidonic acid metabolism—PTGS2—kidney cancer	1.41e-05	0.00241	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	1.4e-05	0.00238	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—PTGS1—kidney cancer	1.37e-05	0.00234	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	1.36e-05	0.00232	CbGpPWpGaD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	1.29e-05	0.00219	CbGpPWpGaD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—POMC—kidney cancer	1.24e-05	0.00211	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	1.21e-05	0.00206	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GSTP1—kidney cancer	1.2e-05	0.00204	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	1.19e-05	0.00203	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—GSTP1—kidney cancer	1.18e-05	0.00201	CbGpPWpGaD
Palonosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	1.18e-05	0.00201	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTT1—kidney cancer	1.13e-05	0.00192	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GSTM1—kidney cancer	1.1e-05	0.00187	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—MYC—kidney cancer	1.1e-05	0.00186	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—GSTM1—kidney cancer	1.09e-05	0.00185	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	1.07e-05	0.00182	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—PTGS1—kidney cancer	1.06e-05	0.0018	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—RAF1—kidney cancer	1.05e-05	0.00179	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—CYP1A1—kidney cancer	1.05e-05	0.00178	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—CYP1A1—kidney cancer	1.03e-05	0.00175	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GSTP1—kidney cancer	1.02e-05	0.00173	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	1.01e-05	0.00172	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—GSTP1—kidney cancer	1e-05	0.0017	CbGpPWpGaD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	9.59e-06	0.00163	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GSTM1—kidney cancer	9.34e-06	0.00159	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—GSTM1—kidney cancer	9.21e-06	0.00157	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ACY1—kidney cancer	9.19e-06	0.00156	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—CYP1A1—kidney cancer	8.85e-06	0.00151	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—CYP1A1—kidney cancer	8.73e-06	0.00149	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTP1—kidney cancer	7.84e-06	0.00133	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PDHB—kidney cancer	7.82e-06	0.00133	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—POMC—kidney cancer	7.79e-06	0.00133	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ACY1—kidney cancer	7.79e-06	0.00132	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	7.74e-06	0.00132	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CCBL1—kidney cancer	7.35e-06	0.00125	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTM1—kidney cancer	7.21e-06	0.00123	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	7.11e-06	0.00121	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	6.83e-06	0.00116	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	6.74e-06	0.00115	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	6.64e-06	0.00113	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PDHB—kidney cancer	6.62e-06	0.00113	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—POMC—kidney cancer	6.6e-06	0.00112	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PPAT—kidney cancer	6.37e-06	0.00108	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GLIPR1—kidney cancer	6.37e-06	0.00108	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CCBL1—kidney cancer	6.23e-06	0.00106	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ACY1—kidney cancer	6.01e-06	0.00102	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—APRT—kidney cancer	5.92e-06	0.00101	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—FH—kidney cancer	5.92e-06	0.00101	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	5.63e-06	0.000958	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GPC3—kidney cancer	5.57e-06	0.000947	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CA2—kidney cancer	5.42e-06	0.000921	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PPAT—kidney cancer	5.4e-06	0.000918	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GLIPR1—kidney cancer	5.4e-06	0.000918	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	5.33e-06	0.000906	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ALAD—kidney cancer	5.28e-06	0.000898	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	5.28e-06	0.000897	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ST3GAL2—kidney cancer	5.15e-06	0.000876	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PDHB—kidney cancer	5.11e-06	0.000869	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—POMC—kidney cancer	5.09e-06	0.000866	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ALDH1A1—kidney cancer	5.04e-06	0.000857	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—APRT—kidney cancer	5.02e-06	0.000853	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—FH—kidney cancer	5.02e-06	0.000853	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	4.91e-06	0.000834	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PGK1—kidney cancer	4.83e-06	0.000821	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SLC5A3—kidney cancer	4.83e-06	0.000821	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CCBL1—kidney cancer	4.81e-06	0.000817	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—LDHB—kidney cancer	4.74e-06	0.000805	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GPC3—kidney cancer	4.72e-06	0.000802	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CA2—kidney cancer	4.59e-06	0.000781	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ALAD—kidney cancer	4.47e-06	0.000761	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ST3GAL2—kidney cancer	4.37e-06	0.000742	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ALDH1A1—kidney cancer	4.27e-06	0.000726	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PPAT—kidney cancer	4.17e-06	0.000708	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GLIPR1—kidney cancer	4.17e-06	0.000708	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CA9—kidney cancer	4.11e-06	0.000698	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PGK1—kidney cancer	4.09e-06	0.000696	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SLC5A3—kidney cancer	4.09e-06	0.000696	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—LDHB—kidney cancer	4.01e-06	0.000682	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—APRT—kidney cancer	3.87e-06	0.000659	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—FH—kidney cancer	3.87e-06	0.000659	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GPC3—kidney cancer	3.64e-06	0.000619	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CA2—kidney cancer	3.54e-06	0.000602	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CRABP1—kidney cancer	3.49e-06	0.000594	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CA9—kidney cancer	3.48e-06	0.000592	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ALAD—kidney cancer	3.45e-06	0.000587	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	3.4e-06	0.000578	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ST3GAL2—kidney cancer	3.37e-06	0.000573	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ALDH1A1—kidney cancer	3.29e-06	0.00056	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ITPR2—kidney cancer	3.25e-06	0.000552	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PGK1—kidney cancer	3.16e-06	0.000537	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SLC5A3—kidney cancer	3.16e-06	0.000537	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—LDHB—kidney cancer	3.1e-06	0.000527	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTT1—kidney cancer	2.96e-06	0.000503	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ACHE—kidney cancer	2.96e-06	0.000503	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CRABP1—kidney cancer	2.96e-06	0.000503	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SCARB1—kidney cancer	2.8e-06	0.000476	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PTGS1—kidney cancer	2.77e-06	0.000472	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ITPR2—kidney cancer	2.75e-06	0.000468	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PSMD7—kidney cancer	2.72e-06	0.000463	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CA9—kidney cancer	2.68e-06	0.000457	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—BCHE—kidney cancer	2.58e-06	0.000439	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SLC5A5—kidney cancer	2.55e-06	0.000433	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.53e-06	0.000431	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ACHE—kidney cancer	2.51e-06	0.000426	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTT1—kidney cancer	2.51e-06	0.000426	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SLC2A1—kidney cancer	2.46e-06	0.000418	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SCARB1—kidney cancer	2.37e-06	0.000404	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PTGS1—kidney cancer	2.35e-06	0.0004	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PSMD7—kidney cancer	2.3e-06	0.000392	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CRABP1—kidney cancer	2.28e-06	0.000388	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—BCHE—kidney cancer	2.18e-06	0.000371	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SLC5A5—kidney cancer	2.16e-06	0.000367	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ITPR2—kidney cancer	2.12e-06	0.000361	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SLC2A1—kidney cancer	2.08e-06	0.000354	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTP1—kidney cancer	2.05e-06	0.000349	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.02e-06	0.000344	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ABCB1—kidney cancer	1.94e-06	0.00033	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ACHE—kidney cancer	1.94e-06	0.000329	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTT1—kidney cancer	1.94e-06	0.000329	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTM1—kidney cancer	1.89e-06	0.000321	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SCARB1—kidney cancer	1.83e-06	0.000312	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PTGS1—kidney cancer	1.81e-06	0.000308	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP1A1—kidney cancer	1.79e-06	0.000304	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PSMD7—kidney cancer	1.78e-06	0.000302	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.76e-06	0.0003	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTP1—kidney cancer	1.74e-06	0.000296	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—BCHE—kidney cancer	1.69e-06	0.000287	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.67e-06	0.000283	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ABCB1—kidney cancer	1.65e-06	0.00028	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.61e-06	0.000274	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTM1—kidney cancer	1.6e-06	0.000272	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP1A1—kidney cancer	1.51e-06	0.000257	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTP1—kidney cancer	1.34e-06	0.000228	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—POMC—kidney cancer	1.33e-06	0.000227	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ABCB1—kidney cancer	1.27e-06	0.000216	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.24e-06	0.000212	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTM1—kidney cancer	1.23e-06	0.00021	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.17e-06	0.000199	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—POMC—kidney cancer	1.13e-06	0.000192	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PTGS2—kidney cancer	1.06e-06	0.000181	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PTEN—kidney cancer	9.27e-07	0.000158	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PTGS2—kidney cancer	9e-07	0.000153	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—POMC—kidney cancer	8.71e-07	0.000148	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PTEN—kidney cancer	7.85e-07	0.000134	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PTGS2—kidney cancer	6.95e-07	0.000118	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3CA—kidney cancer	6.54e-07	0.000111	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PTEN—kidney cancer	6.06e-07	0.000103	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3CA—kidney cancer	5.54e-07	9.42e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3CA—kidney cancer	4.28e-07	7.27e-05	CbGpPWpGaD
